Liposome is a kind of prospective abiotic drug delivery system for cancer treatment. Novel liposomes modified with PEG, cationic lipids and highly selective molecules achieve better stability, half-life and selectivity as well as less severe side effects. However, novel liposomes are still not nontoxic. PEG on the surface of liposomes interfere the combination of cancer cells and drugs. Cationic liposomes can induce oxidative damage and cytotoxicity to normal tissues. To further improve the safety of liposomal drugs, liposomal drugs must be highly selective to cancer tissues and cancer cells, at the same time, induce minimum damage to normal cells. It is necessary to gather several advantages of novel liposomes. The ideal targeted drug delivery system is like a multistage rocket. Firstly, the liposomal drugs should be sensitive to the specific environment of cancer tissues and accumulate in there. Secondly, the liposomes could selectively combine with cancer cells by surface modification. Lastly, in cancer cells, drugs release from the carriers rapidly. What's more, form the records of clinical researches, the side effects induced by liposomal drugs, such as acute infusion reaction and hand-foot syndrome(HFS), are also unignorable. More attention should be paid to these safety problems in new liposomal drugs research and development.

脂质体是一种用于癌症治疗的前瞻性非生物药物递送系统。用PEG，阳离子脂质和高选择性分子修饰的新型脂质体具有更好的稳定性，半衰期和选择性，并且副作用较小。但是，新型脂质体仍然不是无毒的。脂质体表面的PEG会干扰癌细胞和药物的结合。阳离子脂质体可诱导对正常组织的氧化损伤和细胞毒性。为了进一步提高脂质体药物的安全性，脂质体药物必须对癌组织和癌细胞具有高度选择性，同时对正常细胞的损害最小。有必要收集新型脂质体的几个优点。理想的靶向药物输送系统就像一个多级火箭。首先，脂质体药物应对癌组织的特定环境敏感并在其中积累。其次，脂质体可以通过表面修饰选择性地与癌细胞结合。最后，在癌细胞中，药物迅速从载体中释放出来。而且，从临床研究的记录来看，脂质体药物引起的副作用，如急性输液反应和手足综合征（HFS），也是不可忽视的。在新脂质体药物的研究和开发中，应更加重视这些安全性问题。脂质体药物引起的副作用，如急性输注反应和手足综合征（HFS），也是不可忽视的。在新脂质体药物的研究和开发中，应更加重视这些安全性问题。脂质体药物引起的副作用，如急性输注反应和手足综合征（HFS），也是不可忽视的。在新脂质体药物的研究和开发中，应更加重视这些安全性问题。